HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
Clinical trials for HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER explained in plain language.
Never miss a new study
Get alerted when new HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER trials appear
Sign up with your email to follow new studies for HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Bladder cancer duo: BCG plus immunotherapy drug shows promise in early trial
Disease control OngoingThis phase 3 trial is testing whether adding the immunotherapy drug durvalumab to standard BCG treatment can safely control high-risk non-muscle-invasive bladder cancer. About 100 adults who have never received BCG before will get both treatments for up to a year. The main goal i…
Matched conditions: HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for bladder cancer patients avoiding bladder removal
Disease control OngoingThis study tests two experimental treatments—TAR-200 (a drug placed inside the bladder) and cetrelimab (an immunotherapy injection)—alone or together, in people with high-risk bladder cancer that came back after BCG therapy. Participants are those who cannot or choose not to have…
Matched conditions: HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Bladder cancer drug delivered directly: a new hope for BCG failures
Disease control OngoingThis study tests an immunotherapy drug called camrelizumab, given directly into the bladder, for people with high-risk non-muscle invasive bladder cancer that did not respond to BCG treatment. The goal is to find a safe dose and see if it can prevent cancer from coming back or ge…
Matched conditions: HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
Phase: PHASE1, PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New combo therapy shows promise in bladder cancer fight
Disease control OngoingThis study tests whether adding the immunotherapy drug durvalumab to standard BCG treatment helps keep high-risk bladder cancer from coming back. About 1,000 adults with non-muscle-invasive bladder cancer who have not had BCG before will receive either the combination or BCG alon…
Matched conditions: HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New bladder cancer device could delay return of tumors without removing bladder
Disease control OngoingThis study tests a new treatment called TAR-200 for people with a high-risk type of bladder cancer that came back after standard therapy (BCG). Participants either receive TAR-200 or standard chemotherapy placed directly into the bladder. The goal is to see if TAR-200 can keep th…
Matched conditions: HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New bladder cancer device offered to patients with no other options
Disease control APPROVED_FOR_MARKETINGThis program gives patients with high-risk non-muscle invasive bladder cancer access to TAR-200 before it is officially approved. TAR-200 is a device placed into the bladder that releases medication over time. It is for patients who have tried all other treatments and cannot join…
Matched conditions: HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Immunotherapy combo shows promise against tough bladder cancer
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard BCG treatment helps people with high-risk non-muscle invasive bladder cancer stay cancer-free longer. About 1,400 participants will receive either BCG alone or BCG plus pembrolizumab. The goal is to …
Matched conditions: HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC